# BioVie Inc.

BioVie Inc. is a public company headquartered in Carson City, NV, United States.

## Company overview

- **Legal name:** BIOVIE INC.
- **Former names in filing history:** NANOANTIBIOTICS, INC. (2013-07-02 to 2016-07-22)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Carson City, NV, United States
- **Incorporated in:** NV
- **Fiscal year end:** June 30
- **SEC CIK:** 0001580149

## About

BioVie is a clinical-stage company developing investigational therapies for neurological and neurodegenerative disorders and advanced liver disease. Its research includes bezisterim, formerly known as NE3107; the candidate remains investigational. On September 11, 2026, BioVie entered an at-the-market stock-offering arrangement that permitted sales from time to time without requiring them. That agreement provided financing capacity rather than establishing that the full amount had been raised. Its reported principal executive office is in Carson City, NV (United States). For fiscal 2026, ended 2026-06-30, its originally reported results included a net loss of USD 22,072,863; cash used in operations of USD 19,024,806. At that year-end, it reported total assets of USD 14,250,462 and cash and cash equivalents of USD 8,977,370.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2026 (period ended 2026-06-30)

- **Net income:** -$22.1M (USD -22,072,863)
- **Total assets:** $14.3M (USD 14,250,462)
- **Cash and equivalents:** $9.0M (USD 8,977,370)
- **Operating cash flow:** -$19.0M (USD -19,024,806)

### FY2025 (period ended 2025-06-30)

- **Net income:** -$17.5M (USD -17,542,120)
- **Total assets:** $21.6M (USD 21,562,199)
- **Cash and equivalents:** $17.5M (USD 17,544,547)
- **Operating cash flow:** -$19.0M (USD -19,025,205)

### FY2024 (period ended 2024-06-30)

- **Net income:** -$32.1M (USD -32,120,533)
- **Total assets:** $25.2M (USD 25,208,345)
- **Cash and equivalents:** $23.8M (USD 23,843,798)
- **Operating cash flow:** -$27.9M (USD -27,945,024)

### FY2023 (period ended 2023-06-30)

- **Net income:** -$50.3M (USD -50,255,815)
- **Total assets:** $35.1M (USD 35,104,730)
- **Cash and equivalents:** $19.5M (USD 19,460,883)
- **Operating cash flow:** -$40.3M (USD -40,252,881)

## Recent SEC filings

- Form DEF 14A — filed 2026-09-28 — period 2026-09-28 — DEF 14A
- Form 8-K — filed 2026-09-14 — period 2026-09-11 — CURRENT REPORT
- Form 10-K — filed 2026-08-13 — period 2026-06-30 — FORM 10-K FOR PERIOD ENDED JUNE 30, 2026
- Form 8-K — filed 2026-08-06 — period 2026-08-06 — CURRENT REPORT
- Form S-1 — filed 2026-07-17 — FORM S-1 REGISTRATION STATEMENT
- Form 10-Q — filed 2026-05-11 — period 2026-03-31 — FORM 10-Q FOR PERIOD ENDING MARCH 31, 2026
- Form 10-Q — filed 2026-02-06 — period 2025-12-31 — FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 2025
- Form 8-K — filed 2025-11-13 — period 2025-11-10 — CURRENT REPORT
- Form 8-K — filed 2025-11-12 — period 2025-11-10 — CURRENT REPORT
- Form 10-Q — filed 2025-11-10 — period 2025-09-30 — FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2025
- Form DEF 14A — filed 2025-09-25 — period 2025-09-25 — DEF 14A
- Form 10-K — filed 2025-08-15 — period 2025-06-30 — FORM 10-K

---

Updated: 2026-10-15T20:59:03.086Z

Canonical page: https://altss.com/profile/biovie-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology